COVID-19 Vaccine Related Codes

COVID-19 Vaccine Codes

Preview Posting of COVID-19 Vaccine Codes and Crosswalk for Currently Authorized Vaccines and Anticipation of Potential Vaccine Availability under Emergency Use Authorization (EUA)

Note: Codes will become effective only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA)

The codes and crosswalk for candidate COVID-19 vaccines will be posted for preview in phases as the late-stage clinical trials for candidate vaccines progress. Additional vaccines or codes will be added to this list as they enter late-stage clinical trials or prepare applications for FDA authorization.

The following downloadable table provides a summary of the currently authorized vaccine codes and a preview of the vaccine codes that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines.

To support this effort, the CDC is working closely with data partners responsible for the creation and distribution of vaccine codes and drug compendia publishers to coordinate the release of codes in advance of potential EUAs to enable systems and users that require these codes to prepare in advance.

The codes for these vaccines are also included in the vaccine code set files unless otherwise noted in the table.  Additional code details and fields values are included in the vaccine code sets.

American Medical Association (AMA) COVID-19 CPT® vaccine product and administration codes are now available on the AMA web site.  The CPT vaccine product codes are included in the Preview COVID-19 table and the CDC vaccine code sets.  You can access further information regarding the COVID-19 CPT codes, as well as the associated coding guidance, using the following link:

https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codesexternal icon

Download the Preview Table for US vaccine administration only: Excel Versionexcel icon

COVID-19 vaccine codes and crosswalks are provided in anticipation of potential vaccine availability under an approved Biologics License Application (BLA), Emergency Use Authorization (EUA), or as a potential vaccine submission for EUA (Pre-EUA). Codes will become effective for US vaccine administrations only upon EUA issuance and/or BLA approval of COVID-19 vaccine(s) by the FDA. All CVX codes are associated to the new Vaccine Group “COVID-19.” CPT Codes shown are product codes. CPT administrative codes for doses are available on the AMA website. CPT product codes are added as the AMA approves and makes them available.

COVID-19 vaccine codes and crosswalks are provided in anticipation of potential vaccine availability under an approved Biologics License Application (BLA), Emergency Use Authorization (EUA), or as a potential vaccine submission for EUA (Pre-EUA) as of 10/13/2021. Codes will become effective for US vaccine administrations only upon EUA issuance and/or BLA approval of COVID-19 vaccine(s) by the FDA. All CVX codes are associated to the new Vaccine Group “COVID-19.” CPT Codes shown are product codes. CPT administrative codes for doses are available on the AMA website. CPT product codes are added as the AMA approves and makes them available.
Manufacturer FDA Authorization
(BLA, EUA, Pre-EUA)
Sale Proprietary Name Product Description Unit of Sale NDC10 (UOS) UoS Package Unit of Use NDC10 (UOU) UoU Presentation CVX Code CVX Long Description CVX Short Description MVX Code CPT Product Code CPT Description
Janssen Products, LP EUA-authorized (18+) Janssen COVID-19 Vaccine

(BLUE CAP)

5×10^10 viral particles/0.5 mL for adult 18+ 59676-580-15 CARTON, 10 MULTI-DOSE VIALS 59676-580-05 VIAL, MULTI-DOSE 212 SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL JSN 91303 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5×1010 viral particles/0.5 mL dosage, for intramuscular use
Moderna US, Inc. EUA-authorized (18+) Moderna COVID-19 Vaccine

(RED CAP)

100 mcg/0.5 mL for adult 18+ (existing product) 80777-273-99 CARTON, 10 MULTI-DOSE VIAL 5 mL EACH 80777-273-10 VIAL, 5 mL, MULTI-DOSE VIAL 207 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose MOD 91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use
80777-273-98 CARTON, 10 MULTI-DOSE VIAL 7 mL EACH 80777-273-15 VIAL, 7 mL, MULTI-DOSE VIAL
Moderna US, Inc. EUA-authorized (18+) Moderna COVID-19 Vaccine

(RED CAP)

50 mcg/0.25 mL for booster adult 18+ (existing product), drawn from same vial as primary series 80777-273-99 CARTON, 10 MULTI-DOSE VIAL 5 mL EACH 80777-273-10 VIAL, 5 mL, MULTI-DOSE VIAL 207 MOD 91306 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use
80777-273-98 CARTON, 10 MULTI-DOSE VIAL 7 mL EACH 80777-273-15 VIAL, 7 mL, MULTI-DOSE VIAL
Moderna US, Inc. EUA – authorized (18+) Moderna COVID-19 Vaccine Booster

(BLUE CAP)

50 mcg/0.50 mL for booster adult 18+, new concentration 80777-275-99 CARTON, 10 MULTI-DOSE VIAL 2.5 mL EACH 80777-275-05 VIAL, 2.5 mL, MULTI-DOSE VIAL 221 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose MOD 91309 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use
Moderna US, Inc. Pre-EUA Authorization Moderna COVID-19 Vaccine
Pediatric Vaccine (BLUE CAP)
50 mcg/0.50 mL pediatric primary series for ages 6 yrs to <12 years 80777-277-99 CARTON, 10 MULTI-DOSE VIAL 2.5 mL EACH 80777-277-05 VIAL, 2.5 mL, MULTI-DOSE VIAL 227 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 50 mcg/0.5 mL dose COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose MOD NA NA
Moderna US, Inc. Pre-EUA Authorization Moderna COVID-19 Vaccine
Pediatric Vaccine (BLUE CAP)
25 mcg/0.25 mL dose pediatric primary series for ages 6 mo to <6 years 80777-279-99 CARTON, 10 MULTI-DOSE VIAL 2.5 mL EACH 80777-279-05 VIAL, 2.5 mL, MULTI-DOSE VIAL 228 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 25 mcg/0.25 mL dose COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose MOD NA NA
Pfizer-BioNTech EUA-authorized for ages 12 yrs + Pfizer-BioNTech COVID-19 Vaccine

(PURPLE CAP)

(Original product formulation)

30 mcg/0.3 mL for primary series, IC 3rd dose, boosters 59267-1000-2 CARTON, 195 MULTI-DOSE VIALS 59267-1000-1 MULTI-DOSE VIAL 208 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose PFR 91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use
59267-1000-3 CARTON, 25 MULTI-DOSE VIALS
Pfizer-BioNTech EUA-authorized for ages 12 yrs +

Note: BLA-licensed for (16+)

Pfizer-BioNTech COVID-19 Vaccine

(GRAY CAP)

(Tris-sucrose formulation)

30 mcg/0.3 mL for primary series, IC 3rd dose, boosters 59267-1025-3 CARTON, 25 MULTI-DOSE VIALS 59267-1025-1 VIAL, 2.25 mL, MULTI-DOSE VIAL 217 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose PFR 91305 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
59267-1025-4 CARTON, 10 MULTI-DOSE VIALS
Pfizer-BioNTech EUA-authorized for ages 5 yrs to < 12 yrs Pfizer-BioNTech COVID-19 Vaccine

(ORANGE CAP)

(Tris-sucrose formulation)

10 mcg/0.2 mL for primary series, IC 3rd dose 59267-1055-4 CARTON, 10 MULTI-DOSE VIALS 59267-1055-1 VIAL, 2 mL, MULTI-DOSE VIAL 218 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose PFR 91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
Pfizer-BioNTech Pre-EUA for ages 6 mo to <5 yrs Pfizer-BioNTech COVID-19 Vaccine

(MAROON CAP)

(Tris-sucrose formulation)

3 mcg/0.2 mL for primary series 59267-0078-4 CARTON, 10 MULTI-DOSE VIALS 59267-0078-1 VIAL, 2 mL, MULTI-DOSE VIAL 219 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose PFR 91308 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
Novavax, Inc. Pre-EUA Authorization Novavax COVID-19 Vaccine 5 mcg/0.5 mL, primary series, adult 80631-100-10 CARTON, 10 VIAL, MULTI-DOSE 80631-100-01 VIAL, MULTI-DOSE, 5 mL 211 SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL dose COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL NVX 91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use
Sanofi Pasteur Pre-EUA Authorization Sanofi Pasteur COVID-19 Vaccine, primary series, adult 10mcg/0.5mL dose, including added AS03 adjuvant, primary series No production planned for adult series vaccine in U.S. market at this time 226 SARS-COV-2 (COVID-19) vaccine, D614, prefusion spike recombinant protein subunit (CoV2 preS dTM), AS03 adjuvant added, preservative free, 10mcg/0.5mL dose COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL PMC NA NA
Sanofi Pasteur Pre-EUA Authorization Sanofi Pasteur COVID-19 Vaccine, booster dose, adult 5mcg/0.5mL dose, including added AS03 adjuvant, booster dose 49281-618-20 10 MULTI-DOSE VIALS, ANTIGEN ONLY 49281-618-78 VIAL, MULTI-DOSE, ANTIGEN 225 SARS-COV-2 (COVID-19) vaccine, D614, prefusion spike recombinant protein subunit (CoV2 preS dTM), AS03 adjuvant added, preservative free, 5mcg/0.5mL dose COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL PMC NA NA
AstraZeneca Pharmaceuticals LP Pre-EUA Authorization AstraZeneca COVID-19 Vaccine 5×10^10 viral particles/0.5 mL, adult No active NDC codes for U.S. Market at this time 210 SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL ASZ 91302 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5×1010 viral particles/0.5 mL dosage, for intramuscular use

Unspecified US COVID-19 Vaccine CVX Code

Unspecified US COVID-19 Vaccine CVX Code
CVX Short Description CVX Code CVX Long Description Note Vaccine Status
SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED 213 SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED Unspecified code for COVID-19 not to be used to record patient US administration. May be used to record historic US administration if product is not known.  CVX code 500 should be used to record Non-US vaccine where product is not known. Inactive

The following vaccines and associated tradenames have been approved by the FDA under BLA License. They are listed separately because while they may represent the same formulations as the EUA authorized and labeled products listed above, the NDCs listed with the new BLA licensed tradenames in the FDA BLA approval or the FDA Structured Product Labels (SPL) are not currently being produced by the manufacturers while EUA product is available.

The following vaccines and associated tradenames have been approved by the FDA under BLA License. They are listed separately because while they may represent the same formulations as the EUA authorized and labeled products listed above, the NDCs listed with the new BLA licensed tradenames in the FDA BLA approval or the FDA Structured Product Labels (SPL) are not currently being produced by the manufacturers while EUA product is available.
Manufacturer FDA Authorization
(BLA, EUA, Pre-EUA)
Sale Proprietary Name Product Description Unit of Sale NDC10 (UOS) UoS Package Unit of Use NDC10 (UOU) UoU Presentation
Pfizer-BioNTech BLA-licensed for ages 16+ COMIRNATY 30 mcg/0.3 mL for adult 16+ (original formula) 0069-1000-02 CARTON, 195 MULTI-DOSE VIALS 0069-1000-01 VIAL, 2 mL, MULTI-DOSE VIAL COMINARTY products are not orderable at this time. NDCs are listed per FDA Structured Product Label (SPL) document for the BLA licensed product.  These codes are not included in CDC Vaccine Code Set files at this time.  Pfizer has provided the following statement regarding the COMINARTY  branded NDCs and labels:

“Pfizer received FDA BLA license on 8/23/2021 for its COVID-19 vaccine for use in individuals 16 and older (COMIRNATY).  At that time, the FDA published a BLA package insert that included the approved new COVID-19 vaccine tradename COMIRNATY and listed 2 new NDCs (0069-1000-03, 0069-1000-02) and images of labels with the new tradename.

Pfizer subsequently received approval to amend its FDA BLA License on December 16, 2021 to include its tris-sucrose formulation COVID-19 vaccine for use in individuals 16 and older (COMIRNATY).  At that time, the FDA published a BLA package insert that included the approved new COVID-19 vaccine tradename COMIRNATY and listed 3 new NDCs (0069-2025-10, 0069-2025-25, 0069-2025-01) and images of labels with the new tradename.

At present, Pfizer does not plan to produce any product with these new NDCs and labels over the next few months while EUA authorized product is still available and being made available for U.S. distribution.  As such, the CDC, AMA, and drug compendia may not publish these new codes until Pfizer has determined when the product will be produced with the BLA labels.”

00069-1000-03 CARTON, 25 MULTI-DOSE VIALS
Pfizer-BioNTech BLA-licensed for ages 16+ COMIRNATY 30 mcg/0.3 mL for adult 16+ (Same as EUA tris sucrose formula) 0069-2025-10 CARTON, 10 MULTI-DOSE VIALS 0069-2025-01 VIAL, 2 mL, MULTI-DOSE VIAL
0069-2025-25 CARTON, 25 MULTI-DOSE VIALS
Moderna US, Inc. BLA-licensed for ages 18+ SPIKEVAX 0.5 mL dose  (same as original EUA formula) 80777-100-99 CARTON, 10 MULTI-DOSE VIALS, EACH VIAL CONTAINING 5.5 mL NA VIAL, 5.5 mL, MULTI-DOSE VIAL SPIKEVAX products are not orderable at this time. NDCs are listed per FDA Structured Product Label (SPL) document for the BLA licensed product.  These codes are not included in CDC Vaccine Code Set files at this time.  Moderna has provided the following statement regarding the SPIKEVAX  branded NDCs and labels:

“Moderna received FDA BLA license on January 31, 2022, for its COVID-19 vaccine SPIKEVAX (COVID-19 Vaccine, mRNA) for use in individuals 18 and older. At that time, the FDA published a BLA package insert that included the new approved trade name SPIKEVAX and listed 2 new NDCs (80777-100-99, 80777-100-98).

At present, Moderna does not plan to produce any product with these new NDCs and labels over the next few months while EUA authorized Moderna COVID-19 Vaccine product is still available and being made available for U.S. distribution. As such, the CDC, AMA, and drug compendia may delay publishing these new codes until Moderna has determined when the product will be produced with the BLA labels.”

80777-100-98 CARTON, 10 MULTI-DOSE VIALS, EACH VIAL CONTAINING 7.5 mL NA VIAL, 7.5 mL, MULTI-DOSE VIAL

Download the Preview Table for Non-US vaccine administration only: Excel Versionexcel icon

Preview Posting of COVID-19 Vaccine Codes and Crosswalks to be used for Non-US vaccine administration. All COVID-19 related CVX codes are associated to the Vaccine Group “COVID-19”. CVX and MVX codes are identified for vaccines that have received emergency authorization from the World Health Organization (WHO), US Food and Drug Administration (FDA) or both. CVX codes have also been added without associated MVX for vaccines that are manufactured and administered outside the US but which have not been authorized by the WHO. The list of vaccines not authorized by the WHO may be incomplete. The list of vaccines indicated to be WHO-authorized will be updated periodically as the CDC monitors WHO published information.

Preview Posting of COVID-19 Vaccine Codes and Crosswalks to be used for Non-US vaccine administration. All COVID-19 related CVX codes are associated to the Vaccine Group “COVID-19”. Data as of 10/13/2021. CVX and MVX codes are identified for vaccines that have received emergency authorization from the World Health Organization (WHO), US Food and Drug Administration (FDA) or both. CVX codes have also been added without associated MVX for vaccines that are manufactured and administered outside the US but which have not been authorized by the WHO. The list of vaccines not authorized by the WHO may be incomplete. The list of vaccines indicated to be WHO-authorized will be updated periodically as the CDC monitors WHO published information.
CVX Code CVX Long Description CVX Short Description CVX Note CVX Status MVX Code MVX Manufacturer Product Tradename(s)
207 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg or 50 mcg dose COVID-19, mRNA, LNP-S, PF, 100 mcg or 50 mcg dose EUA 12/18/2020, 2-dose vaccine.  Used to record Moderna vaccines administered in the US and in non-US locations (includes tradename Spikevax) Active MOD Moderna US, Inc. Moderna COVID-19 Vaccine (non-US Spikevax)
208 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose EUA 12/11/2020, 2-dose vaccine. Used to record Pfizer vaccines administered in the US and in non-US locations (includes tradename Comirnaty) Active PFR Pfizer, Inc Pfizer-BioNTech COVID-19 Vaccine (US-EUA), COMIRNATY (US-BLA), COMIRNATY (Non-US)
210 SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL Potential EUA, 2-dose vaccine. AstraZeneca vaccine is authorized by the WHO and recognized towards immunity in the US. Non-US WHO authorized tradenames/identifiers include VAXZEVRIA, AZD1222, ChAdOx1 nCoV-19, COVISHIELD Non-US ASZ AstraZeneca AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD)
212 SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL EUA 02/27/2021, 1-dose vaccine. Used to record Janssen/J&J vaccines administered in the US and in non-US locations Active JSN Janssen Janssen (J&J) COVID-19 Vaccine
510 SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm) COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) WHO authorized pandemic vaccine.  Recognized towards immunity in US Non-US SPH Sinopharm-Biotech Sinopharm (BIBP) COVID-19 Vaccine
511 SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac) COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) WHO authorized pandemic vaccine.  Recognized towards immunity in US Non-US SNV Sinovac Coronavac (Sinovac) COVID-19 Vaccine
512 SARS-COV-2 COVID-19 Virus Like Particle (VLP) Non-US Vaccine Product (Medicago, Covifenz) SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) Pandemic Non-US Vaccine not Authorized by WHO – ACIP does recognize towards immunity in US Non-US MDO Medicago, Inc Covifenz
500 SARS-COV-2 COVID-19 Non-US Vaccine, Specific Product Unknown COVID-19 Non-US Vaccine, Product Unknown Pandemic Non-US Covid Administration – specific CVX or product unknown Non-US
501 SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (QAZCOVID-IN) COVID-19 IV Non-US Vaccine (QAZCOVID-IN) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward  immunity in US Non-US
502 SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN) COVID-19 IV Non-US Vaccine (COVAXIN) Pandemic Non-US Vaccine Authorized by WHO 11-3-2021, recognized toward immunity in US, https://extranet.who.int/pqweb/vaccines/who-recommendation-bharat-biotech-international-ltd-covid-19-vaccine-whole-virion Non-US BBI Bharat Biotech International Limited COVAXIN (Bharat) COVID-19 Vaccine
503 SARS-COV-2 COVID-19  Live Attenuated Virus Non-US Vaccine Product (COVIVAC) COVID-19 LAV Non-US Vaccine (COVIVAC) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward  immunity in US Non-US
504 SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light) COVID-19 VVnr Non-US Vaccine (Sputnik Light) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward  immunity in US Non-US
505 SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik V) COVID-19 VVnr Non-US Vaccine (Sputnik V) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward  immunity in US Non-US
506 SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CanSino Biological Inc./Beijing Institute of Biotechnology COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward  immunity in US Non-US
507 SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences) COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences Pandemic Non-US Vaccine not Authorized by WHO – not counted toward  immunity in US Non-US
508 SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product  (Jiangsu Province Centers for Disease Control and Prevention) COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward  immunity in US Non-US
509 SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (EpiVacCorona) COVID-19 PS Non-US Vaccine (EpiVacCorona) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward  immunity in US Non-US
513 SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom, Zifivax) SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
514 SARS-COV-2 COVID-19 DNA Non-US Vaccine Product (Zydus Cadila, ZyCoV-D) SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
515 SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Medigen, MVC-COV1901) SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
516 SARS-COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
517 SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Biological E Limited, Corbevax) SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US

COVID-19 Emergency Use Authorization Recipient and Caregiver Fact Sheets

Preview Posting of Codes for Emergency Use Authorization (EUA) Fact Sheets for Recipients and Caregivers

Vaccine information statements (VISs), used only for licensed vaccines, will not be available for COVID-19 vaccines while they are under Emergency Use Authorization (EUA). For vaccines under an EUA, the FDA requires a vaccine-specific Fact Sheet for Recipients and Caregivers be provided to vaccine recipients or their caregivers.

The COVID-19 vaccine-related codes are provided in anticipation of potential vaccine availability under an EUA. If a vaccine is not authorized, the code will be retired.

The FDA issued Emergency Use Authorization for the Moderna COVID-19 vaccine on Friday December 18, 2020.  Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccineexternal icon

The FDA issued Emergency Use Authorization for the Pfizer BioNTech COVID-19 vaccine on Friday December 11, 2020.  Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccineexternal icon

The FDA issued Emergency Use Authorization for the Janssen (Johnson & Johnson) COVID-19 vaccine on Saturday February 27, 2021.  Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccineexternal icon

The following downloadable VIS code files will include the new EUA Fact Sheet for Recipients records:

Preview Posting of Codes for Emergency Use Authorization (EUA) Fact Sheets for Recipients and Caregivers”
CVX Code EUA Recipient/Caregiver Fact Sheet Description Document Barcode String Edition Date Edition Status HTML URL PDF URL VIS GDTI document code
207, 221 COVID-19 Moderna Vaccine EUA Recipient-Caregiver Fact Sheet 253088698300034911210601 3/29/2022 Current https://www.cdc.gov/vaccines/covid-19/eua/modernatx.html https://www.cdc.gov/vaccines/covid-19/eua/modernatx.pdfpdf icon 0886983000349
227 COVID-19 Moderna EUA Recipient-Caregiver Fact Sheet – Pediatric 6yrs to <12yrs 253088698300050911220501 6/1/2022 Current https://www.cdc.gov/vaccines/covid-19/eua/moderna-children-6-years-under-12-years.html https://www.cdc.gov/vaccines/covid-19/eua/moderna-children-6-years-under-12-years.pdfpdf icon 0886983000509
228 COVID-19 Moderna EUA Recipient-Caregiver Fact Sheet – Pediatric 6mo to <6yrs 253088698300051611220501 6/1/2022 Current https://www.cdc.gov/vaccines/covid-19/eua/moderna-children-6-months-under-6-years.html https://www.cdc.gov/vaccines/covid-19/eua/moderna-children-6-months-under-6-years.pdfpdf icon 0886983000516
208, 217 COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet – 12 years and older 253088698300033211210501 5/17/2022 Current https://www.cdc.gov/vaccines/covid-19/eua/pfizer.html https://www.cdc.gov/vaccines/covid-19/eua/pfizer.pdfpdf icon 0886983000332
218 COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet- Pediatric 5yrs to <12 yrs 253088698300042411211001 5/17/2022 Current https://www.cdc.gov/vaccines/covid-19/eua/pfizer-children.html https://www.cdc.gov/vaccines/covid-19/eua/pfizer-children.pdfpdf icon 0886983000424
219 COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet- Pediatric <5 yrs 253088698300048611220101 3/1/2022 Current https://www.cdc.gov/vaccines/covid-19/eua/pfizer-children-under-5-years.html https://www.cdc.gov/vaccines/covid-19/eua/pfizer-children-under-5-years.pdfpdf icon 0886983000486
212 COVID-19 Janssen Vaccine EUA Recipient-Caregiver Fact Sheet 253088698300036311210201 5/5/2022 Current https://www.cdc.gov/vaccines/covid-19/eua/janssen.html https://www.cdc.gov/vaccines/covid-19/eua/janssen.pdfpdf icon 0886983000363
211 COVID-19 Novavax EUA Recipient-Caregiver Fact Sheet 253088698300037011220101 6/1/2022 Current https://www.cdc.gov/vaccines/covid-19/eua/novavax.html https://www.cdc.gov/vaccines/covid-19/eua/novavax.pdfpdf icon 0886983000370
225 COVID-19 Sanofi-GSK EUA Recipient-Caregiver Fact Sheet – Booster 253088698300052311220401 6/1/2022 Current https://www.cdc.gov/vaccines/covid-19/eua/sanofi.html https://www.cdc.gov/vaccines/covid-19/eua/sanofi.pdfpdf icon 0886983000523

*Edition Date represents the date of update printed on the actual fact sheet document published by the FDA.  It may not be the same as the EUA authorization date or the date embedded in the Document Barcode String.

Page last reviewed: May 17, 2022